483
Supernus Pharmaceuticals, Inc.Supernus Pharmaceuticals, Inc. – FDA 483, Feb 3, 2017
Record Details
Supernus Pharmaceuticals, Inc. in Rockville, MD, was inspected regarding its analytical laboratory operations. The inspection revealed a significant issue with the timely submission of quarterly periodic adverse drug experience reports (PSURs) for its products Trokendi XR and Oxtellar XR. Approximately 40% of all PSURs for these products were submitted late to the FDA.
View Company Profile
ID · 1869cce8-730f-465f-a5b7-3dae643d1f96
Other documents for Supernus Pharmaceuticals, Inc.
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.